Last reviewed · How we verify

Estrace 0.01% Vaginal Cream

University of California, Irvine · FDA-approved active Small molecule

Estrace 0.01% Vaginal Cream is a Estrogen replacement therapy Small molecule drug developed by University of California, Irvine. It is currently FDA-approved for Vaginal atrophy and urogenital symptoms associated with menopause, Atrophic vaginitis.

Estrace vaginal cream delivers estradiol directly to vaginal tissues to restore estrogen levels and relieve symptoms of vaginal atrophy and menopausal urogenital changes.

Estrace vaginal cream delivers estradiol directly to vaginal tissues to restore estrogen levels and relieve symptoms of vaginal atrophy and menopausal urogenital changes. Used for Vaginal atrophy and urogenital symptoms associated with menopause, Atrophic vaginitis.

At a glance

Generic nameEstrace 0.01% Vaginal Cream
SponsorUniversity of California, Irvine
Drug classEstrogen replacement therapy
TargetEstrogen receptor alpha (ERα) and estrogen receptor beta (ERβ)
ModalitySmall molecule
Therapeutic areaGynecology / Endocrinology
PhaseFDA-approved

Mechanism of action

Estradiol is a potent estrogen that binds to estrogen receptors in vaginal epithelial cells, promoting cell proliferation, increasing vaginal blood flow, and restoring normal vaginal pH and lubrication. This local hormone replacement therapy alleviates symptoms such as vaginal dryness, itching, burning, and dyspareunia associated with menopause or estrogen deficiency.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Estrace 0.01% Vaginal Cream

What is Estrace 0.01% Vaginal Cream?

Estrace 0.01% Vaginal Cream is a Estrogen replacement therapy drug developed by University of California, Irvine, indicated for Vaginal atrophy and urogenital symptoms associated with menopause, Atrophic vaginitis.

How does Estrace 0.01% Vaginal Cream work?

Estrace vaginal cream delivers estradiol directly to vaginal tissues to restore estrogen levels and relieve symptoms of vaginal atrophy and menopausal urogenital changes.

What is Estrace 0.01% Vaginal Cream used for?

Estrace 0.01% Vaginal Cream is indicated for Vaginal atrophy and urogenital symptoms associated with menopause, Atrophic vaginitis.

Who makes Estrace 0.01% Vaginal Cream?

Estrace 0.01% Vaginal Cream is developed and marketed by University of California, Irvine (see full University of California, Irvine pipeline at /company/university-of-california-irvine).

What drug class is Estrace 0.01% Vaginal Cream in?

Estrace 0.01% Vaginal Cream belongs to the Estrogen replacement therapy class. See all Estrogen replacement therapy drugs at /class/estrogen-replacement-therapy.

What development phase is Estrace 0.01% Vaginal Cream in?

Estrace 0.01% Vaginal Cream is FDA-approved (marketed).

What are the side effects of Estrace 0.01% Vaginal Cream?

Common side effects of Estrace 0.01% Vaginal Cream include Vaginal irritation or burning, Headache, Breast tenderness, Vaginal discharge.

What does Estrace 0.01% Vaginal Cream target?

Estrace 0.01% Vaginal Cream targets Estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ) and is a Estrogen replacement therapy.

Related